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AbstrACt
Introduction Measures of epidemiological burdens are 
an important contribution to estimating disease severity 
and determining the at-risk populations for seasonal 
influenza. In the absence of these data, it is extremely 
difficult for policy-makers to decide on how to distribute 
limited resources. This systematic review will synthesise 
the literature on reported burden of seasonal influenza (eg, 
morbidity and mortality) in sub-Saharan Africa.
Method and analysis We will include published 
epidemiological studies that capture the burden estimation 
of seasonal influenza between 1 January 2000 and 
31 August 2018. Studies that have reported disease 
burden estimates associated to influenza-like illness, 
acute respiratory illness, acute lower respiratory illness, 
severe acute respiratory illness and severe or very severe 
pneumonia using laboratory-confirmed influenza cases will 
be included. We will perform a multiple electronic database 
search in PubMed, Embase, African Journals Online, 
Cochrane, Web of science, CINAHL and Google scholar for 
eligible studies. The reference lists of relevant studies will 
also be hand-searched for potentially eligible studies. The 
titles and abstracts of identified records will be screened 
independently by two authors. The full-text articles of 
potentially eligible studies will be assessed independently 
by two authors. Discrepancies will be resolved by 
discussion, and by a third author if the first two authors 
fail to come to a consensus. The measures of the burden 
of influenza will be aggregated using a meta-analysis 
for homogeneous studies and narrative synthesis if the 
studies are heterogeneous. The strength of the evidence 
will be assessed using the Grading of Recommendations 
Assessment, Development and Evaluation approach.
Ethics and dissemination This systematic review will 
use publicly available data; and as such, no formal ethical 
review is required. Our findings will be published in a 
peer-reviewed journal and also disseminated through 
conferences and stakeholder meetings.
PrOsPErO registration number CRD42017074091.
IntrOduCtIOn
Seasonal influenza is a respiratory transmit-
table infection caused by different subtypes 
(types A, B, C and D) of influenza viruses. 
It is a public health problem, causing severe 
illness in about 3–5 million people and 
responsible for 290 000–650 000 deaths 
worldwide each year.1 It further remains an 
important source of economic loss world-
wide. The total economic loss in the USA 
due to the burden of influenza amounts to 
US$87.1 billion every year.2 Hospitalisation 
due to seasonal influenza leads to losses in 
working days due to sickness, reduction in 
quality of life due to secondary infections, 
increased school absenteeism and increased 
use of hospital resources.3
This condition affects individuals of all 
ages but complications are more common in 
those younger than 5 years of age, frail adults 
over 65, pregnant women and persons with 
chronic medical conditions. The age-specific 
mortality is highest in individuals over 65 
years of age, accounting for 90% of deaths.4 
Attack rates in susceptible populations, such 
as school-going children or those in nursing 
homes have been found to be as high as 
40%–50%.5 Clinical influenza attack rates 
range from 34% to 67% and rate of hospi-
talisation varies, with children admitted to 
hospital with acute lower respiratory infec-
tion (ALRI), from which influenza virus is 
identified, varying from 0% to 15.6%.6 Severe 
strengths and limitations of this study
 ► This systematic review will assess the epidemiolog-
ical burdens of seasonal influenza without placing 
any restriction on language.
 ► The search for relevant studies will include both 
published and unpublished to minimise the risk for 
publication bias.
 ► The strength of the evidence in this review will be 
assessed using the Grading of Recommendations 
Assessment, Development and Evaluation approach.
 ► A wide variation in the case definition and diagnostic 
of influenza may lead to inaccurate estimates of the 
disease burden.
 ► The studies that will be included in this review are 
observational studies which are more prone to re-
porting biases and may overestimate the burden of 
the disease.
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ALRI would generally include pneumonia but also most 
commonly present itself as bronchiolitis in children. 
Mortality rates in children due to pneumonia are highest 
in Africa.7 The research on the global burden of paedi-
atric influenza indicates that 99% of deaths in children 
under 5 years of age are due to lower respiratory tract 
infections.8
Although seasonal influenza produces lower level 
activity in space and time, its cumulative mortality from 
regular epidemics are greater overall than that of rare 
pandemics. For instance, cumulative seasonal influenza 
mortality accrued between 1957 and 1968 exceeded the 
mortality of the influenza pandemics of 1957 and 1968 in 
the USA. The influenza pandemics of the 1957 and 1968 
caused about 98 000 excess deaths but seasonal influenza 
deaths were double the excess deaths between 1957 and 
1968, excluding the pandemic years.9
Although much is known about the effects of seasonal 
influenza, including global estimates of burden of influ-
enza, the majority of studies are derived from developed 
countries. The burden of seasonal influenza in Africa is 
not fully known. The purpose of this study is to synthe-
sise the existing studies that have reported the burden of 
seasonal influenza in sub-Saharan Africa.
Why is it important to do this review?
WHO recommends reinforcement of routine epidemi-
ological and virological surveillance in order to ensure 
timely detection of outbreaks and management of cases.10 
In 2002, WHO pledged to support the Integrated Disease 
Surveillance and Response (IDSR) systems which carry 
out monitoring and assessment of diseases, including 
the burden of seasonal influenza. Through surveillance 
systems, it is anticipated that hospitals and laboratories 
would document useful data for assessing the burden of 
seasonal influenza. However, there is a dearth of epidemi-
ological information on seasonal influenza including its 
impacts (mortality, attack rates, susceptibility and hospi-
talisation) in sub-Saharan African countries. The aim of 
this review is to investigate the epidemiological burden 
of seasonal influenza and highlight its epidemiological 
patterns in sub-Saharan African countries. Our findings 
will contribute to the better understanding of the burden 
of seasonal influenza and will be useful in the planning 
for and response to seasonal influenza outbreaks in terms 
of prevention and treatment.
MEthOds
Patient and public involvement
Patients were not involved in the design of this study.
ElIgIbIlIty CrItErIA
type of studies to be included
Epidemiological studies conducted in sub-Saharan 
African countries and published between 1 January 2000 
and 31 August 2018 reporting on the burden of seasonal 
influenza will be included. These dates coincides with the 
existence of the IDSR system in Africa. We will include 
published estimates from studies deriving their data 
from sentinel surveillance systems or healthcare facilities 
in which human influenza infection has been verified 
using a valid laboratory test such as a reverse transcrip-
tase PCR (RT-PCR). Since influenza transmission occurs 
throughout the tropical and subtropical areas in Africa, 
we will consider studies with data reported weekly or 
monthly for at least a year. The peak periods in influenza 
in the tropics are between March and September but 
tend to vary from year to year depending on the type and 
subtype of human influenza in circulation.11 12 Studies 
that estimate the disease burden using modelling tech-
niques will be excluded.
Participants
We will include studies that stratify influenza rates in the 
following age groups: 0 to <2 years, 2 to <5 years, 5 to <15 
years, 15 to <50 years, 50 to <65 years and over 65 years. 
Where studies are unable to report age-stratified estimates 
within the proposed age groups, we will report rates as 
suggested in the studies. We will pull and group similar 
studies together according to the subgroup population 
based on WHO case definition of influenza. WHO case 
definitions vary across age groups and across study sites. 
All age-specific data for inclusion will be well defined 
in terms of numerators (case count) and denominators 
(population at risk). We will exclude all studies that use 
data reported between 31 January 2009 and 1 November 
2010 including all studies where study duration overlaps 
or combines the pandemic and non-pandemic periods. 
The 2009 pandemic influenza was declared in April 2009 
and by August 2010 it was declared over.13 This is based 
on the assumption that the pandemic virus (H1N1) was 
actively circulating for 6–8 weeks before and after the 
pandemic period.
types of outcome measures
In order to be considered for inclusion, studies should 
explicitly report one or more epidemiological burden 
estimates. Burden estimates refer to mortality rates, 
attack rates, hospitalisation or admission rates, incidence 
rates or period prevalence rates associated with influen-
za-like illness (ILI) and severe acute respiratory illness 
(SARI). We will also adopt the following definition of the 
outcome measures. Mortality rate is defined as a measure 
of the number of deaths in a specific age group due to 
seasonal influenza divided by population of age group 
expressed in 1000 person-years. Overall attack rate refers 
to number of new cases of influenza during the specified 
time divided by the total number of specified population 
at start of time interval. Age-specific attack rate is calcu-
lated as a number of influenza illnesses among a specified 
age group divided by the total number of persons in that 
specified age population who were at risk to influenza at 
the start of the observation period. Hospitalisation rate is 
the number of influenza inpatient admissions discharged 
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over a specific time and geographical area divided by the 
population in that age group, expressed in terms of 1000 
people days. Incidence rate is the number of new cases per 
population at risk in a given time period whereas period 
prevalence rate is a measurement of new and pre-existing 
of all individuals affected by the disease over a specified 
period of time divided by total number of people in that 
population. As far as prevalence estimates are concerned, 
we will only focus on period prevalence.
Case definitions of IlI and sArI
We will adopt WHO case definitions for ILI and SARI used 
between 1999 and 2018. The 1999 WHO case definition 
of ILI was defined as ‘a sudden onset of fever, a tempera-
ture >38°C and a cough or sore throat in the absence 
of another diagnosis’.14 In 2018, ILI was defined as ‘an 
acute respiratory illness (ARI) with measured tempera-
ture of ≥38°C and cough, with onset within 10 days’.15 In 
1999, SARI definition did not exist but in 2009 it was offi-
cially defined as ‘a sudden onset of fever >38°C, cough 
or sore throat, shortness of breath or difficulty breathing 
and requiring hospitalisation. For those less than 5 years 
of age, pneumonia was used as criteria including cough 
or difficulty breathing.16 The 2018 definition of SARI 
(including ARI, ALRI and severe or very severe pneu-
monia) was ‘an ARI with a history of fever or measured 
fever of ≥38°C and cough, with onset within the past 10 
days, requiring hospitalisation.15 We will pull studies that 
report laboratory-confirmed influenza in patients with 
pneumonia that matches the International Classification 
of Disease, Ninth Revision codes (ICD-9 codes; 488.01, 
488.11 and ICD-10 codes; J09.01, J09.11, J10.0). WHO 
case definitions for ILI and SARI have changed many 
times, in 2011, 2014 and 2018 in order to facility valid 
comparison of disease occurrence over a period of time, 
and increase the sensitivity and specificity in reporting.
search method for identification of studies
We will construct a comprehensive search strategy using 
keywords and Medical Subject Headings (MESH) terms 
in PubMed, Embase, African Journals Online, Cochrane, 
Web of science, CINAHL and Google scholar for rele-
vant studies. We will conduct a database search followed 
by hand-searching of reference sections of all relevant 
studies. The MeSH terms influenza (human) OR inter-
pandemic influenza, sentinel or virological surveillance, 
mortality, morbidity, hospitalisation, admission rates, clin-
ical attack rates, ILI (outpatients), SARI, ALRI and Africa 
will be used to combine searches systematically. The 
search strategy for PubMed is shown in box 1, but we plan 
to modify and run slightly different search strategy across 
the different databases. We will not place any restriction 
on language but will limit our search to studies in sub-Sa-
haran Africa.
selection of studies
All the identified titles and abstracts will be examined 
independently for potential eligibility by two authors (EZS 
and AM). Discrepancies will be resolved by consensus and 
if necessary by arbitration by a third author (CSW). The 
full texts of potentially eligible studies will be retrieved, 
and screened independently by two authors (EZS and 
box 1 search strategy
(((‘africa’[MeSH Terms] OR ‘africa’[All Fields]) AND ((((((‘epidemiol-
ogy’[Subheading] OR ‘epidemiology’[All Fields] OR ‘incidence’[All 
Fields] OR ‘incidence’[MeSH Terms]) OR (‘epidemiology’[Subheading] 
OR ‘epidemiology’[All Fields] OR ‘prevalence’[All Fields] OR ‘preva-
lence’[MeSH Terms])) OR (‘mortality’[Subheading] OR ‘mortality’[All 
Fields] OR ‘mortality’[MeSH Terms])) OR (‘hospitalisation’[All Fields] 
OR ‘hospitalisation’[MeSH Terms] OR ‘hospitalisation’[All Fields])) 
OR ADMISSION[All Fields]) OR ((‘influenza, human’[MeSH Terms] OR 
(‘influenza’[All Fields] AND ‘human’[All Fields]) OR ‘human influen-
za’[All Fields] OR ‘influenza’[All Fields]) AND ASSOCIATED[All Fields] 
AND ILLNESS[All Fields]))) AND (((((((‘influenza, human’[MeSH Terms] 
OR (‘influenza’[All Fields] AND ‘human’[All Fields]) OR ‘human influ-
enza’[All Fields] OR ‘influenza’[All Fields]) AND LIKE[All Fields] AND 
ILLNESS[All Fields]) OR (SEVERE[All Fields] AND ACUTE[All Fields] AND 
(‘respiratory tract infections’[MeSH Terms] OR (‘respiratory’[All Fields] 
AND ‘tract’[All Fields] AND ‘infections’[All Fields]) OR ‘respiratory tract 
infections’[All Fields] OR (‘respiratory’[All Fields] AND ‘infections’[All 
Fields]) OR ‘respiratory infections’[All Fields]))) OR ((‘virology’[MeSH 
Terms] OR ‘virology’[All Fields] OR ‘virologic’[All Fields]) AND (‘epide-
miology’[Subheading] OR ‘epidemiology’[All Fields] OR ‘surveillance’[All 
Fields] OR ‘epidemiology’[MeSH Terms] OR ‘surveillance’[All Fields]))) 
OR ((‘laboratories’[MeSH Terms] OR ‘laboratories’[All Fields] OR ‘labo-
ratory’[All Fields]) AND CONFIRMED[All Fields])) OR ((‘outpatients’[MeSH 
Terms] OR ‘outpatients’[All Fields] OR (‘out’[All Fields] AND ‘patients’[All 
Fields]) OR ‘out patients’(All Fields)) AND VISIT[All Fields])) OR (‘re-
verse transcriptase polymerase chain reaction’[MeSH Terms] OR (‘re-
verse’[All Fields] AND ‘transcriptase’[All Fields] AND ‘polymerase’[All 
Fields] AND ‘chain’[All Fields] AND ‘reaction’[All Fields]) OR ‘reverse 
transcriptase polymerase chain reaction’[All Fields] OR (‘rt’[All Fields] 
AND ‘pcr’[All Fields]) OR ‘rt pcr’[All Fields]))) AND ((((((SEASONAL[All 
Fields] AND (‘influenza, human’[MeSH Terms] OR (‘influenza’[All Fields] 
AND ‘human’[All Fields]) OR ‘human influenza’[All Fields] OR ‘influen-
za’[All Fields])) OR (‘influenza, human’[MeSH Terms] OR (‘influenza’[All 
Fields] AND ‘human’[All Fields]) OR ‘human influenza’[All Fields] OR 
(‘human’[All Fields] AND ‘influenza’[All Fields]))) OR (INTER[All Fields] 
AND (‘pandemics’[MeSH Terms] OR ‘pandemics’[All Fields] OR ‘pan-
demic’[All Fields]) AND (‘influenza, human’[MeSH Terms] OR (‘influ-
enza’[All Fields] AND ‘human’[All Fields]) OR ‘human influenza’[All 
Fields] OR ‘influenza’[All Fields]))) OR ((‘laboratories’[MeSH Terms] OR 
‘laboratories’[All Fields] OR ‘laboratory’[All Fields]) AND CONFIRMED[All 
Fields] AND (‘influenza, human’[MeSH Terms] OR (‘influenza’[All Fields] 
AND ‘human’[All Fields]) OR ‘human influenza’[All Fields] OR ‘influen-
za’[All Fields]))) OR (ACUTE[All Fields] AND (‘respiratory tract infec-
tions’[MeSH Terms] OR (‘respiratory’[All Fields] AND ‘tract’[All Fields] 
AND ‘infections’[All Fields]) OR ‘respiratory tract infections’[All Fields] 
OR (‘respiratory’[All Fields] AND ‘infections’[All Fields]) OR ‘respiratory 
infections’[All Fields]))) OR ((‘influenza, human’[MeSH Terms] OR (‘in-
fluenza’[All Fields] AND ‘human’[All Fields]) OR ‘human influenza’[All 
Fields] OR ‘influenza’[All Fields]) AND ASSOCIATED[All Fields] AND 
ACUTE[All Fields] AND LOWER[All Fields] AND (‘respiratory tract infec-
tions’[MeSH Terms] OR (‘respiratory’[All Fields] AND ‘tract’[All Fields] 
AND ‘infections’[All Fields]) OR ‘respiratory tract infections’[All Fields] 
OR (‘respiratory’[All Fields] AND ‘infections’[All Fields]) OR ‘respiratory 
infections’[All Fields])))
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AM). Disagreements between the first two authors will 
again be resolved by discussion and consensus and by 
arbitration by a third author (CSW) if necessary.
data extraction and management
Two study authors (EZS and AM) will extract data inde-
pendently from eligible studies using a prestructured and 
tested data collection form. The information collected 
using this form will include details on the year the study was 
conducted, setting, study design, methods, participants 
and outcomes, source of funding and risk of bias. The 
two authors will compare the extracted data and discrep-
ancies will be resolved by consensus or by a third author 
(CSW) if relevant. In the event where there are missing 
data from included studies which we deem important, we 
will contact the authors of the studies involved.
risk of bias (quality) assessment
Two independent reviewers will retrieve, screen and assess 
the risk of bias in the identified studies using the risk of 
bias tool by Hoy et al . 17   In context of surveillance, biases 
are often present at the sampling stage of SARI/ALRI/
ILI case counts of which many eligible cases are excluded 
resulting in selection bias. In addition, diagnostic assays 
used to identify cases may lead to misclassification bias. 
For example, RT-PCR identifies more cases than immu-
nofluorescence assays. .
data and sensitivity analysis
A descriptive analysis of the study outcomes will be under-
taken if studies are not eligible to be pooled for burden 
estimates. This will include studies with burden estimates 
that are not representative of the catchment population. 
Eligible studies will be stratified by type of population 
(ie, community or hospital setting, etc), surveillance 
type (ie, active or passive surveillance) and type of influ-
enza case definitions (including whether it is based on 
1999, 2014 or 2018 case definition) in order to compare 
similar designs. We will also stratify the burden estimates 
for ILI and SARI by age or risk group. In an event, there 
is multiple reporting in a study we will combine all the 
studies or use the study with the most complete dataset.
Quantitative estimates, that is, annual incidence, period 
prevalence and mortality of influenza, and 95% CIs will be 
obtained from all eligible studies and pooled for a statistical 
meta-analysis by use of STATA software version 15 if we find 
that studies are similar. If burden estimates are reported by 
week or month, we will calculate yearly burden estimates 
based on methods provided in WHO manual for estimating 
disease burden associated with seasonal influenza.18 Where 
studies provide relevant data for the catchment popula-
tion, we will pool burden proportions of all cases sampled 
among SARI cases from whom clinical specimen were 
tested by week/month/year by dividing the total number 
of SARI cases by month/week/year and multiplying it 
by 100%. We will adjust for true total number of influen-
za-associated SARI cases per week/month/year by scaling 
up the number of influenza positive SARI cases by the 
proportion of SARI cases tested. To estimate the proportion 
of ILI cases attributable to laboratory-confirmed influenza 
illness without population denominators require data on 
case counts (ie, number of ILI cases positive for influenza 
virus using laboratory tests) divided by number of ILI cases 
from whom clinical specimens were collected for diagnostic 
testing multiplied by 100. To estimate number of influen-
za-associated ILI, we will adjust the proportion influenza-as-
sociated ILI by week, month or year multiplied by total 
number of ILI cases by week, month or year. Step-by-step 
formulas are presented in in WHO manual for estimating 
disease burden associated with seasonal influenza.18
We will use a meta-analysis to aggregate estimate 
measures. The random-effects models and fixed-effects 
models of regression coefficients will be used for pooled 
data analysis. If necessary, all studies of good methodolog-
ical quality will be combined. We anticipate heterogeneity 
in the pooled studies due to different case definitions for 
SARI/ILI and origin of data (active and passive surveil-
lance), thus, heterogeneity will be tested using the χ2 test 
and I2 test statistic. We will consider a significance level of 
α=0.1 for χ2 test and I2 statistic of >50% to reflect signif-
icant heterogeneity. Heterogeneity and non-heteroge-
neity will be tested by deliberately dropping studies with 
high risk of bias from the analyses one at a time. If statis-
tical heterogeneity is present, a subgroup analyses will be 
undertaken to examine the source of the poor data quality. 
We will include case definitions of influenza, passive or 
active studies, representation of the catchment area, age, 
gender, seasonality (tropical or subtropical), duration 
and type of study as covariates in the meta-analysis. Where 
there is significant heterogeneity, meta-analysis will not 
be performed. Only studies with similar risk of bias assess-
ment will be pooled in a meta-analysis. We will define 
country burden disease estimates yielded from passive 
sentinel surveillance data (eg, ILI) as a lower threshold 
and upper threshold for active sentinel surveillance data 
(eg, SARI). Passive sentinel surveillance substantially 
yields lower estimates compared with active surveillance 
data. A forest plot on all data points and random-effects 
estimates will be generated to give insight to the analyses. 
The reviewers will assess the strength of the evidence 
according to the Grading of Recommendations Assess-
ment, Development and Evaluation approach.19 This 
approach rates the strength of the evidence by taking into 
account five factors: methodological quality, directness of 
evidence, heterogeneity, precision and risk of publication 
bias.
reporting of this review
We wrote this protocol following the Preferred Reporting 
Items for Systematic Review and Meta-Analyses (PRISMA) 
Protocols guidelines. PRISMA focuses on ways in which 
authors can ensure the transparent and complete 
reporting of systematic reviews and meta-analyses.20 
The findings of this review and any amendments will be 
reported according to the PRISMA statement.
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Ethics and communication
Our findings will be published in a peer-review journal 
and subsequently disseminated to policy-makers through 
conferences and stakeholder meetings.
discussion and study limitations
There is a lack of epidemiological and laboratory surveil-
lance data on the burden of seasonal influenza in Africa.21 
This lack of information specifically attack rates, suscep-
tibility and hospitalisation may undermine the role of 
seasonal influenza vaccination programme specifically in 
terms of how it should be implemented. Careful under-
standing of seasonal influenza, through continuous collec-
tion of surveillance and monitoring data of influenza 
activity taking place at any time of the year, will assist poli-
cy-makers in preparing for and to strengthening capacity 
for seasonal influenza surveillance and reporting. The 
overall understanding of the burden of seasonal influ-
enza in African settings will subsequently provide infor-
mation for treatment, prevention and control strategies 
of seasonal influenza such as giving the vaccines to high-
risk groups first. We also hope that strengthening surveil-
lance systems for seasonal influenza that report on the 
burden of viruses will rapidly help detect and send early 
signals of an impending new or severe influenza activity 
in humans. Seasonal influenza burden estimates that 
provide baseline data can provide valuable information 
with which to compare annual influenza outbreaks with 
unusual outbreak events.18 This information can serve as 
a predictive indicator for new events such as an influenza 
pandemic and systematically aid pandemic planners to 
plan for additional capacities and resources (stockpile 
of antivirals and antibiotics, etc) needed to deal with a 
severity of a new pandemic activity.22
We anticipate several limitations in our study related to 
bias in influenza reporting and estimating burden of the 
disease. First, pooled data from studies will be limited to 
respiratory infections such as ILI and SARI. As such there 
is possibility of underestimating influenza-related burden 
caused by other clinical manifestation such as myocardial 
event triggered by influenza infection. Second, ILI surveil-
lance data do not have a known population denominators 
and many people in the communities or catchment areas 
may not report influenza-associated disease, thus making 
it difficult to extrapolate, for example, incidence rates. 
Assuming enough information is provided in the studies, 
we will adjust the estimates by using the methodology 
provided in a similar study23 to ours. Third, while we will 
take precautions to review studies for quality and rele-
vance, often bias resulting from case definitions (error 
in coding cases), diagnostic sampling and diagnostic 
assays are inevitable in eligible studies, thus difficult to 
determine precisely the disease burden estimations once 
we pool data for analyses. We deliberately intend to use 
different WHO case definitions of SARI and ILI. However, 
the implication of this is that much older version of case 
definition is highly sensitive to children under the age of 
5 and less sensitive to older children and adults. Further 
implication of the use of different case definitions is that 
pooled estimates may not be a reflection of true influ-
enza burden in the population. We intend to reconcile 
the different case definitions (eg, SARI cases) in different 
studies by matching them to hospitalised severe ALRI and 
pneumonia and influenza (ie, ICD-9 and ICD-10) making 
sure there are comparable between themselves and help 
in harmonisation and interpretation of data.
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